Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.
In vitro screening of thiacetazone derivatives indicated that two derivatives, SRI-286 and SRI-224, inhibited a panel of 25 Mycobacterium avium complex (MAC) isolates at concentrations of 2 micro g/ml or lower. In mice, SRI-224 and thiacetazone had no significant activity against the MAC in livers and spleens, but treatment with SRI-286 resulted in significant reduction of bacterial loads in livers and spleens. A combination of SRI-286 and moxifloxacin was significantly more active than single drug regimens in liver and spleen.
Bermudez
Luiz E
LE
Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco, California 94115, USA. luiz.bermudez@oregonstate.edu
Reynolds
Robert
R
Kolonoski
Peter
P
Aralar
Pricilla
P
Inderlied
Clark B
CB
Young
Lowell S
LS
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001372:Aza Compounds; D015169:Colony Count, Microbial; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones; D006801:Humans; D008099:Liver / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D015269:Mycobacterium avium Complex; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy* / Q000382:microbiology; D011804:Quinolines; D013154:Spleen / Q000382:microbiology; D013828:Thioacetazone / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; C477304:SRI 224; C477303:SRI 286; D013828:Thioacetazone; D000077266:Moxifloxacin